Medical leaders meet to commemorate National Biocontainment Lab construction start
Main Category: Bio-terrorism / TerrorismArticle Date: 06 Aug 2005 - 12:00 PDT
| Patient / Public: | ![]() |
5 (1 votes) |
| Healthcare Prof: | ![]() |
5 (1 votes) |
Texas scientific and political leaders will turn ceremonial shovels at noon on Wednesday, Aug. 10, to commemorate a milestone in a work-in-progress, the nation's first National Biocontainment Laboratory at the University of Texas Medical Branch at Galveston.
The formal groundbreaking ceremony, to be held in William C. Levin Hall on the UTMB campus, marks the beginning of the construction phase of the Galveston National Laboratory. The project has been under design since UTMB received the $110 million construction grant from National Institutes of Health in October 2003.
A scientific symposium will follow featuring international leaders in the field of biodefense and emerging infectious diseases. The symposium will also be held at Levin Hall on the UTMB campus.
"The Galveston National Laboratory (GNL) is the first complex of its size and scope undertaken in the United States on an academic campus," said Dr. Stanley M. Lemon, director of UTMB's Institute for Human Infections and Immunity.
"This facility will make it possible to accelerate important scientific work to develop new vaccines, diagnostics and treatments for diseases like anthrax, plague, hemorrhagic fevers, typhus, West Nile fever, SARS, influenza and drug-resistant tuberculosis," he said.
Once completed, the six-story structure will house more than 12,000 square feet of maximum-containment biosafety level 4 (BSL4) laboratories where researchers from UTMB and other institutions will safely study disease-causing viruses and bacteria that could emerge naturally or be used by bioterrorists. A total 83,000 square feet of research space will also incorporate BSL2 and BSL3 labs.
The GNL is expected to be completed in June 2008 at a cost of about $167 million.
Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health will join Texas Senator Kay Bailey Hutchison, James Huffines, chairman of the Board of Regents of the University of Texas System, members of the UT Board of Regents, UTMB president Dr. John D. Stobo, faculty and friends to celebrate this achievement.
The symposium, "Facing the Future: Biodefense and Emerging Infectious Diseases," will be held from 2 to 5 p.m. in the North Auditorium of Levin Hall. Co-chairs are Dr. C.J. Peters, Director of Biodefense, and Dr. David H. Walker, Executive Director of UTMB's Center for Biodefense and Emerging Infectious Diseases. The aim of the symposium is to explore the challenges posed by bioterrorism and emerging infectious diseases, and to consider the future role of the GNL in meeting these challenges.
Presenters include Dr. Fauci (vision, aims, and biodefense research agenda for the NIAID), Dr. Mike Osterholm (threats posed by bioterrorism and emerging infections), Dr. Rob Webster (Avian flu), Dr. Heinz Feldman (the Marburg outbreak and filovirus vaccine efforts), and Dr. George Poste (issues relating to research transition and commercialization of the research products.)
Dr. Fauci, Sen. Hutchinson, Mr. Huffines, Dr. Stobo, Dr. Lemon, and all presenters, Dr. Osterholm, Dr. Webster, Dr. Feldman, Dr. Poste will be available for interviews, immediately after the ceremony, around 12:30 p.m. Interviews may be arranged by contacting Tom Curtis (409) 772-2455 or Marsha Canright, (409) 772-8785, or the news line at (409) 772-NEWS.
A tour of the construction site and/or individual interviews may also be arranged.
Tom Curtis
tcurtis@utmb.edu
409-772-2455
University of Texas Medical Branch at Galveston
http://www.utmb.edu
Visit our bio-terrorism / terrorism section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/28724.php>
APA
http://www.medicalnewstoday.com/releases/28724.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



